Observational data from the Women's Health Initiative show a 48% increased risk of developing diabetes mellitus with statins. Results from two meta-analyses of randomized trials of statins with 120,000 participants have indicated a dose-dependent, but more-modest, relationship between statins and new-onset diabetes. Careful interpretation of pharmacoepidemiological data is required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baigent, C. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
Sattar, N. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375, 735–742 (2010).
Waters, D. D. et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57, 1535–1545 (2011).
Preiss, D. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305, 2556–2564 (2011).
British Heart Foundation. Statins now make up fifth of all cardiovascular medicines [online], (2011).
Culver, A. L. et al. Statin use and risk of diabetes in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172, 144–152 (2012).
Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med. 357, 2248–2261 (2007).
Tavazzi, L. et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231–1239 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N. Sattar is a consultant for, and has received honoraria from, AstraZeneca, MSD, and Pfizer, and has received a grant or research support from Pfizer. D. Preiss declares no competing interests.
Rights and permissions
About this article
Cite this article
Preiss, D., Sattar, N. Statins and new-onset diabetes—the important questions. Nat Rev Cardiol 9, 190–192 (2012). https://doi.org/10.1038/nrcardio.2012.15
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2012.15
This article is cited by
-
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]
Diabetologia (2015)
-
Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?
International Journal of Clinical Pharmacy (2012)
